Nasdaq

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress ...

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a ...
Nasdaq

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery ...

Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60 ...
The American Journal of Managed Care

Lack of Diversity in Pulmonary Fibrosis Genetic Studies Limits Clinical Applicability: Ayodeji Adegunsoye, MD, PhD, MSc

Ayodeji Adegunsoye, MD, PhD, MSc, highlights how the underrepresentation of minority populations in pulmonary fibrosis genetic studies hinders accurate disease risk prediction and broader clinical ...